Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3201 in advanced prostate cancer
NCT07172126Phase 2Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2025
- Primary completion
- Apr 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3201 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
TQB3201
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07172126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172126.